Moving Beyond the Business Case for QbD

The case has already been made that Quality by Design can make drug manufacturing both faster and cheaper. But success depends as much on organizational issues as technical ones, write Ted Fuhr and Katy George of McKinsey & Co.

If you are not automatically redirected, follow this link:

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments